Mizuho Maintains Bearish View on Relypsa (RLYP) Despite Q1 Top-Line Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Relypsa (RLYP) Financing Does Not Prevent 2016 Acquisition - Wedbush
May 9, 2016 10:40 AM EDTIn a note dated May 6, Wedbush analyst Liana Moussatos reiterated an Outperform rating while trimming her price target on Relypsa, Inc. (NASDAQ: RLYP) to $51.00 (from $52.00), saying the financing provides a runway into mid-2017 and does not prevent a 2016 acquisition.
Moussatos commented, "The recent $150MM debt financing alleviates 2016 cash... More
Debt Financing Buys Relypsa (RLYP) Time to Negotiate a Sale - Brean
May 5, 2016 10:11 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and $26 price target on Relypsa, Inc. (NASDAQ: RLYP) as Q1 beat consensus estimates, though the commercial launch of Veltassa continues to be slow.
"While Veltassa is still attractive in the long... More
Relypsa (RLYP) Tops Q1 EPS by 20c
May 4, 2016 4:09 PM EDTRelypsa (NASDAQ: RLYP) reported Q1 EPS of ($1.26), $0.20 better than the analyst estimate of ($1.46). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $6.88 million.
We made great progress in our first full quarter with Veltassa on the market. We saw solid month-over-month growth of prescriptions, reported early success with payers, including agreements with the two largest pharmacy benefit managers, and have had a positive reception from treating physicians, said John A. Orwin, president and chief executive officer of Relypsa. Yesterday, we announced a debt financing that will... More
